Biotech Values

[smittypa]

"A bit further to go in the clinic".
Agreed, but, compassionate use for (OMS 721) more than one indication in Europe, seems positive. They have tried OMS 721 on most Soliris indications, with success, but not PNH. OMS 906 (MASP 3), which targets more than the C5 pathway, and has demonstrated single dose efficacy for 16 days in a primate model, will enter the clinic this year. Market cap of RARX looks rich, versus Omeros.